With coronavirus cases surging in the United States, the need for a vaccine is growing increasingly urgent, but federal officials have sought in recent days to reassure the public that the approval process for any potential vaccine will be thorough and transparent. Pfizer and BioNTech announced Wednesday that the latest data from their vaccine study indicates their shot is 95% effective, and they intend to formally apply for emergency authorization (EUA) in the U.S. within days. The companies claimed no serious side effects had been detected, and the most common problem was fatigue reported by 4% of participants. To read the full story.
- COVID-19 is still more deadly than the flu, and N.J. health officials expect cases to rise in the coming days and weeks.
- Study Identifies Behaviors That Helped Couples Weather the Pandemic.
- iJOBS Workshop: SciPhD Leadership and Business Skills for Scientists
- New NJACTS Publication
- NIH Grant Writing Virtual Mini-Course – Sign Up Now